Shares of Rhythm Pharmaceuticals RYTM were up 36.6% yesterday after it reported positive top-line data from a phase II study ...

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and ...

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 ...

Here are some of the largest recent moves: FMR LLC added 1,575,266 shares (+1392.7%) to their portfolio in Q1 2025, for an estimated $83,441,840; WESTFIELD CAPITAL MANAGEMENT CO LP added 1,341,092 ...

Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data ...

Elektron's Analog Four MKII and Analog Rytm MKII are both serious high-end instruments. They're $1,399 and $1,699 respectively. But, despite being at the top of the Elektron heap, they've been ...

RYTM’s Next Steps of Development for Bivamelagon. Building on the encouraging data from the phase II study, Rhythm Pharmaceuticals intends to engage with regulatory authorities in the United ...